Kaival Gundavda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kaival Gundavda has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Shraddha Patkar
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
8 shared publications - Mahesh Goel
Department of Surgical Oncology Tata Memorial Hospital and Homi Bhabha National Institution Mumbai India
7 shared publications - Anant Ramaswamy
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
6 shared publications - Vikram Chaudhari
Division of GI and HPB Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, India
6 shared publications - Manish Suresh Bhandare
Gastrointestinal and Hepato-Pancreato-Biliary Services, Department of Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Hospital, Parel, Mumbai, India
5 shared publications - Shailesh Vinayak Shrikhande
Division of Gastrointestinal and Hepato-Pancreato-Biliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra 400012, India
5 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in World Journal of Surgery
Defining the Role of Staging Laparoscopy in the Management of the Gallbladder Cancers: A Single Institution Experience
Introduction: Despite advances in imaging and extensive staging work‐up, occult metastases may still be encountered at laparotomy in patients with apparently resectable gallbladder cancer (GBC), resulting in nontherapeutic surgery. This study evaluates the incremental yield of staging laparoscopy (SL) in detecting radiologically occult metastases in resectable GBC and its role in routine staging. Methods: A prospectively maintained database of patients operated for GBC at a high volume institution was analyzed to calculate the diagnostic yield of SL and the percentage of missed metastases by modern imaging analysis but subsequently diagnosed on SL. In the univariate and multivariate logistic regression, the following binary variables were evaluated to identify predictors of metastasis on SL: (i) NACT (neoadjuvant chemotherapy) receipt: yes versus no; (ii) serum carbohydrate antigen 19–9 (CA19‐9) level: > 1000 u/mL versus ≤ 1000 U/mL; (iii) 18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) scan result: equivocal versus negative (positive results were excluded from this analysis as they would not have proceeded to SL without additional workup); (iv) clinical stage: locally advanced versus early; (v) incidental GBC: yes versus no; (vi) tumor grade: moderate/poorly differentiated versus well differentiated. Results: The SL was incorporated into the diagnostic and management pathway of 330 GBC patients. SL was performed (i) as a staging prior to a planned radical cholecystectomy ( n = 210, 63.6%) and (ii) prior to initiating systemic therapy ( n = 120, 36.4%). The diagnostic yield of SL for detection of metastases over cross‐sectional imaging was 11.5% ( n = 38). Reasons for inoperability on laparotomy were metastatic 16b1 lymph node (LN) ( n = 19, 50%), locally unresectable disease ( n = 15, 39.5%), peritoneal metastasis ( n = 2, 5.3%), and liver metastasis ( n = 2, 5.3%). The reason for locally unresectable disease was right hepatic artery encasement at the porta hepatis. Regression analysis showed that the significant predictors for metastatic disease on SL were equivocal uptake on 18 FDG PET/CT scan ( p = < 0.001) and prior NACT ( p = 0.026). Conclusion: SL provides an incremental detection of radiologically occult metastasis in up to 11.5% patients. The study underscores the benefit of SL and suggests that it should be incorporated in the management of all GBC patients.
- 9 October 2026
- Published by Wiley in World Journal of Surgery
Defining the Role of Staging Laparoscopy in the Management of the Gallbladder Cancers: A Single Institution Experience
Introduction: Despite advances in imaging and extensive staging work‐up, occult metastases may still be encountered at laparotomy in patients with apparently resectable gallbladder cancer (GBC), resulting in nontherapeutic surgery. This study evaluates the incremental yield of staging laparoscopy (SL) in detecting radiologically occult metastases in resectable GBC and its role in routine staging. Methods: A prospectively maintained database of patients operated for GBC at a high volume institution was analyzed to calculate the diagnostic yield of SL and the percentage of missed metastases by modern imaging analysis but subsequently diagnosed on SL. In the univariate and multivariate logistic regression, the following binary variables were evaluated to identify predictors of metastasis on SL: (i) NACT (neoadjuvant chemotherapy) receipt: yes versus no; (ii) serum carbohydrate antigen 19–9 (CA19‐9) level: > 1000 u/mL versus ≤ 1000 U/mL; (iii) 18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) scan result: equivocal versus negative (positive results were excluded from this analysis as they would not have proceeded to SL without additional workup); (iv) clinical stage: locally advanced versus early; (v) incidental GBC: yes versus no; (vi) tumor grade: moderate/poorly differentiated versus well differentiated. Results: The SL was incorporated into the diagnostic and management pathway of 330 GBC patients. SL was performed (i) as a staging prior to a planned radical cholecystectomy ( n = 210, 63.6%) and (ii) prior to initiating systemic therapy ( n = 120, 36.4%). The diagnostic yield of SL for detection of metastases over cross‐sectional imaging was 11.5% ( n = 38). Reasons for inoperability on laparotomy were metastatic 16b1 lymph node (LN) ( n = 19, 50%), locally unresectable disease ( n = 15, 39.5%), peritoneal metastasis ( n = 2, 5.3%), and liver metastasis ( n = 2, 5.3%). The reason for locally unresectable disease was right hepatic artery encasement at the porta hepatis. Regression analysis showed that the significant predictors for metastatic disease on SL were equivocal uptake on 18 FDG PET/CT scan ( p = < 0.001) and prior NACT ( p = 0.026). Conclusion: SL provides an incremental detection of radiologically occult metastasis in up to 11.5% patients. The study underscores the benefit of SL and suggests that it should be incorporated in the management of all GBC patients.
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (4)
Predicting clinical benefit response after neoadjuvant chemotherapy in locally advanced gallbladder cancer: retrospective analysis
Background: Neoadjuvant chemotherapy is increasingly used in patients with locally advanced gallbladder cancer (LAGBC). This study investigated factors affecting clinical benefit response (CBR) to neoadjuvant chemotherapy for LAGBC. Methods: All consecutive patients with LAGBC following neoadjuvant chemotherapy, from January 2013 to December 2022, were analyzed for clinical and radiological responses as well as survival outcomes. CBR rates, resectability, and their impact on survival were evaluated. In addition, factors predicting CBR were identified and a predictive nomogram model was developed. Results: Of 401 patients with LAGBC undergoing neoadjuvant chemotherapy, 303 (75.5%) exhibited a CBR. The median overall survival (OS) in patients with a CBR was 25 months, compared with 8.5 months for those without a CBR. Factors predicting a worse CBR rate included age ≥ 55.5 years (hazard ratio (HR) 2.17; 95% confidence interval (c.i.) 1.29 to 3.65), Eastern Cooperative Oncology Group (ECOG) performance status ≥ 1 (HR 2.5; 95% c.i. 1.117 to 5.59), platelet count ≥ 468 × 109/l (HR 2.86; 95% c.i. 1.12 to 6.74), tumour (T) size ≥ 2.1 cm (HR 3.4; 95% c.i. 1.70 to 6.80), T stage ≥ T3 (HR 3.26; 95% c.i. 1.22 to 8.74), and a systemic immune-inflammation index (SII) ≥ 1265.90 (HR 2.34; 95% c.i. 1.27 to 4.30). Of the patients with a CBR, 86% underwent curative surgical resection, with median OS improved to 29.54 months, compared with 11.86 months for those without resection (P < 0.01). Conclusion: A CBR was achieved in 75.5% of patients, with curative surgical resection in 86%. A CBR was associated with improved OS. Anatomical (T size, T stage) and immune–inflammation markers (platelet count, SII) were found to predict a CBR, and could help identify responders to neoadjuvant chemotherapy. This could have implications for treatment strategies, but requires validation in further prospective studies.
- 1 July 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (4)
Open AccessPredicting clinical benefit response after neoadjuvant chemotherapy in locally advanced gallbladder cancer: retrospective analysis
Background: Neoadjuvant chemotherapy is increasingly used in patients with locally advanced gallbladder cancer (LAGBC). This study investigated factors affecting clinical benefit response (CBR) to neoadjuvant chemotherapy for LAGBC. Methods: All consecutive patients with LAGBC following neoadjuvant chemotherapy, from January 2013 to December 2022, were analyzed for clinical and radiological responses as well as survival outcomes. CBR rates, resectability, and their impact on survival were evaluated. In addition, factors predicting CBR were identified and a predictive nomogram model was developed. Results: Of 401 patients with LAGBC undergoing neoadjuvant chemotherapy, 303 (75.5%) exhibited a CBR. The median overall survival (OS) in patients with a CBR was 25 months, compared with 8.5 months for those without a CBR. Factors predicting a worse CBR rate included age ≥ 55.5 years (hazard ratio (HR) 2.17; 95% confidence interval (c.i.) 1.29 to 3.65), Eastern Cooperative Oncology Group (ECOG) performance status ≥ 1 (HR 2.5; 95% c.i. 1.117 to 5.59), platelet count ≥ 468 × 109/l (HR 2.86; 95% c.i. 1.12 to 6.74), tumour (T) size ≥ 2.1 cm (HR 3.4; 95% c.i. 1.70 to 6.80), T stage ≥ T3 (HR 3.26; 95% c.i. 1.22 to 8.74), and a systemic immune-inflammation index (SII) ≥ 1265.90 (HR 2.34; 95% c.i. 1.27 to 4.30). Of the patients with a CBR, 86% underwent curative surgical resection, with median OS improved to 29.54 months, compared with 11.86 months for those without resection (P < 0.01). Conclusion: A CBR was achieved in 75.5% of patients, with curative surgical resection in 86%. A CBR was associated with improved OS. Anatomical (T size, T stage) and immune–inflammation markers (platelet count, SII) were found to predict a CBR, and could help identify responders to neoadjuvant chemotherapy. This could have implications for treatment strategies, but requires validation in further prospective studies.
- Open Access
- 27 May 2025
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 1-11
Correlation between Tomographic and Histopathological Staging in Upfront Resected Gastric Cancer: Enhancing Diagnostic Accuracy in the Era of Perioperative Therapy
Purpose This study aimed to assess the diagnostic accuracy of multidetector contrast-enhanced computerised tomography (MDCT) and to establish a correlation between radiological and histopathological staging in upfront resected localised gastric cancers (GC). Methods All consecutive patients of resectable, localised GC who underwent upfront elective resection between 2010 and 2022 were included. The initial clinical staging determined during multidisciplinary meetings was compared with the pathological stage obtained after surgery. Subsequently, a retrospective, blinded review was conducted to assign a revised clinical staging, and accuracy was correlated. Results The analysis of 138 patients revealed varying accuracy of MDCT in determining the T stage (66.9% for T1/T2, 64.6% for T3, and 87.2% for T4) and N stage (60.8% for N0, 63.7% for N1, and 83.2% for N2). The accuracy for stage group ranged from 71 to 78.65%. There was weak agreement observed between the T, N, and overall stage on clinicopathological correlation. However, a blinded radiology review by oncoradiologists resulted in improved accuracy, particularly in T1/T2 disease, and also improved pathological stage correlation. Conclusions Although MDCT is a valuable initial staging tool for gastric cancer, we found weak agreement between the clinical and the pathological stages in upfront resected gastric cancers. By implementing an expert radiology review and standardising scanning and reporting protocols, we can significantly improve the accuracy and correlation of MDCT with pathology, even for T1/T2 disease. This may help in better selecting patients for upfront surgery versus perioperative chemotherapy, especially in resource-constrained settings.
- 27 May 2025
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 1-11
Open AccessCorrelation between Tomographic and Histopathological Staging in Upfront Resected Gastric Cancer: Enhancing Diagnostic Accuracy in the Era of Perioperative Therapy
Purpose This study aimed to assess the diagnostic accuracy of multidetector contrast-enhanced computerised tomography (MDCT) and to establish a correlation between radiological and histopathological staging in upfront resected localised gastric cancers (GC). Methods All consecutive patients of resectable, localised GC who underwent upfront elective resection between 2010 and 2022 were included. The initial clinical staging determined during multidisciplinary meetings was compared with the pathological stage obtained after surgery. Subsequently, a retrospective, blinded review was conducted to assign a revised clinical staging, and accuracy was correlated. Results The analysis of 138 patients revealed varying accuracy of MDCT in determining the T stage (66.9% for T1/T2, 64.6% for T3, and 87.2% for T4) and N stage (60.8% for N0, 63.7% for N1, and 83.2% for N2). The accuracy for stage group ranged from 71 to 78.65%. There was weak agreement observed between the T, N, and overall stage on clinicopathological correlation. However, a blinded radiology review by oncoradiologists resulted in improved accuracy, particularly in T1/T2 disease, and also improved pathological stage correlation. Conclusions Although MDCT is a valuable initial staging tool for gastric cancer, we found weak agreement between the clinical and the pathological stages in upfront resected gastric cancers. By implementing an expert radiology review and standardising scanning and reporting protocols, we can significantly improve the accuracy and correlation of MDCT with pathology, even for T1/T2 disease. This may help in better selecting patients for upfront surgery versus perioperative chemotherapy, especially in resource-constrained settings.
- 5 May 2025
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 67, 103046
Cystic bone Lesions: Diagnostic pitfalls and therapeutic considerations
- 5 May 2025
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 67, 103046
Cystic bone Lesions: Diagnostic pitfalls and therapeutic considerations
- 22 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (1) , 101868
Optimal treatment strategies for borderline resectable liver metastases from colorectal cancer
- 22 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (1) , 101868
Optimal treatment strategies for borderline resectable liver metastases from colorectal cancer
- 16 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 8764-8765
ASO Visual Abstract: Prognostic Impact of Para-aortic Lymph Node Metastasis in Resected Nonpancreatic Periampullary Cancers
- 16 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 8764-8765
ASO Visual Abstract: Prognostic Impact of Para-aortic Lymph Node Metastasis in Resected Nonpancreatic Periampullary Cancers
- 13 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7911-7912
ASO Visual Abstract: Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
- 13 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7911-7912
ASO Visual Abstract: Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
- 10 August 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (1) , 102401
Liver Resection for Hepatocellular Carcinoma: Recent Advances
- 10 August 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (1) , 102401
Liver Resection for Hepatocellular Carcinoma: Recent Advances
- Open Access
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7870-7881
Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
Background: ‘Textbook Outcome’ (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed to assess the applicability of TO as an outcome measure following liver resection for hepatic neoplasms from a low- to middle-income economy and determine its impact on long-term survival. Based on identified perioperative predictors, we developed and validated a nomogram-based scoring and risk stratification system. Methods: We retrospectively analyzed patients undergoing curative resections for hepatic neoplasms between 2012 and 2023. Rates of TO were assessed over time and factors associated with achieving a TO were evaluated. Using stepwise regression, a prediction nomogram for achieving TO was established based on perioperative risk factors. Results: Of the 1018 consecutive patients who underwent liver resections, a TO was achieved in 64.9% (661/1018). The factor most responsible for not achieving TO was significant post-hepatectomy liver failure (22%). Realization of TO was independently associated with improved overall and disease-free survival. On logistic regression, American Society of Anesthesiologists score of 2 (p = 0.0002), perihilar cholangiocarcinoma (p = 0.011), major hepatectomy (p = 0.0006), blood loss >1500 mL (p = 0.007), and presence of lymphovascular emboli on pathology (p = 0.026) were associated with the non-realization of TO. These independent risk factors were integrated into a nomogram prediction model with the predictive efficiency for TO (area under the curve 75.21%, 95% confidence interval 70.69–79.72%). Conclusion: TO is a realizable outcome measure and should be adopted. We recommend the use of the nomogram proposed as a convenient tool for patient selection and prognosticating outcomes following hepatectomy.
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7870-7881
Open AccessRealizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
Background: ‘Textbook Outcome’ (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed to assess the applicability of TO as an outcome measure following liver resection for hepatic neoplasms from a low- to middle-income economy and determine its impact on long-term survival. Based on identified perioperative predictors, we developed and validated a nomogram-based scoring and risk stratification system. Methods: We retrospectively analyzed patients undergoing curative resections for hepatic neoplasms between 2012 and 2023. Rates of TO were assessed over time and factors associated with achieving a TO were evaluated. Using stepwise regression, a prediction nomogram for achieving TO was established based on perioperative risk factors. Results: Of the 1018 consecutive patients who underwent liver resections, a TO was achieved in 64.9% (661/1018). The factor most responsible for not achieving TO was significant post-hepatectomy liver failure (22%). Realization of TO was independently associated with improved overall and disease-free survival. On logistic regression, American Society of Anesthesiologists score of 2 (p = 0.0002), perihilar cholangiocarcinoma (p = 0.011), major hepatectomy (p = 0.0006), blood loss >1500 mL (p = 0.007), and presence of lymphovascular emboli on pathology (p = 0.026) were associated with the non-realization of TO. These independent risk factors were integrated into a nomogram prediction model with the predictive efficiency for TO (area under the curve 75.21%, 95% confidence interval 70.69–79.72%). Conclusion: TO is a realizable outcome measure and should be adopted. We recommend the use of the nomogram proposed as a convenient tool for patient selection and prognosticating outcomes following hepatectomy.
- Open Access
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (10) , 7078-7079
ASO Author Reflections: Pancreaticoduodenectomy for Isolated Para-Aortic Lymph Node Metastasis in Non-pancreatic Periampullary Cancers: Advocating for Careful Patient Selection and Routine Frozen Section
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (10) , 7078-7079
Open AccessASO Author Reflections: Pancreaticoduodenectomy for Isolated Para-Aortic Lymph Node Metastasis in Non-pancreatic Periampullary Cancers: Advocating for Careful Patient Selection and Routine Frozen Section